MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
76.34
+1.61 (+2.15%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close74.73
Open74.58
Bid75.40 x 900
Ask75.78 x 1100
Day's Range74.46 - 76.82
52 Week Range56.26 - 83.85
Volume13,237,187
Avg. Volume10,949,556
Market Cap197.192B
Beta (3Y Monthly)0.37
PE Ratio (TTM)32.91
EPS (TTM)2.32
Earnings DateApr 30, 2019
Forward Dividend & Yield2.20 (2.65%)
Ex-Dividend Date2019-03-14
1y Target Est87.36
Trade prices are not sourced from all markets
  • Business Wire9 hours ago

    Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Merck , known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma.

  • The Top 10 Biotechnology Companies (JNJ, ROG.VX)
    Investopedia12 hours ago

    The Top 10 Biotechnology Companies (JNJ, ROG.VX)

    Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

  • Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
    Zacks12 hours ago

    Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis

    Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.

  • Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?
    Zacks15 hours ago

    Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

    Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

  • Pfizer Stock Has Positive and Negative Catalysts Going Into Results
    InvestorPlace17 hours ago

    Pfizer Stock Has Positive and Negative Catalysts Going Into Results

    Pfizer (NYSE:PFE) stock has missed out on the exuberant bull market this year, as the indexes have hit all-time highs, but Pfizer stock has fallen about 10% in 2019.Source: Shutterstock Then again, the company's growth has been lagging, and PFE has felt pressure from Washington, DC to reduce its drug prices.But next week we'll get more information on the status of the company, as it will report its first-quarter results. They will be announced on Apr. 30 before the market opens.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Dividend Stocks That Could Double Over the Next Five Years Analysts' expectations for Pfizer stock are fairly muted. For the quarter, on average they predict that its revenues will be $13 billion and its earnings will be 75 cents per share of Pfizer stock By comparison, in the same period a year ago, its revenues were $12.9 billion and its earnings were 77 cents per share.It's important to keep in mind that, when PFE last reported its financial results, it provided full-year revenue guidance of $52 billion to $54 billion. Last year, its top line came in at $53.6 billion.The big issue for Pfizer stock has been its pain killer, Lyrica. This drug, which generated close to $5 billion of revenue last year, will lose its patent protection in June. Moreover, the sales of a number of PFE's other drugs have slowed this year.But PFE's pipeline does look promising, creating potential positive catalysts for PFE stock. Last quarter, the company announced several positive catalysts involving its pipeline. Specifically: * Pfizer and Bristol-Myers Squibb (NYSE:BMY) have been developing a new version of Eliquis, which has been shown to effectively treat the bleeding of heart attack patients. A recent study of Eliquis indicated that its efficacy in this area was significantly better than that of a warfarin combination. * The FDA granted a Breakthrough Therapy Designation for Pfizer's 20-Valent Pneumococcal Conjugate Vaccine (20vPnC). The treatment is supposed to prevent people from getting pneumonia, and it appears to be much more effective than the vaccines that are currently on the market. * The European Commission approved VIZIMPRO, which is a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC). * In Q1, Pfizer continued its big push into the gene-therapy market. The company announced that it had created a partnership with Vivet Therapeutics. The companies will focus on developing a treatment for Wilson disease , a rare condition that leads to copper poisoning. * The FDA approved Pfizer's TRAZIMERA, a treatment for breast cancer.Going forward, a number of Pfizer's major drugs, including Xeljanz and Ibrance., should be approved as treatments for additional diseases. Furthermore, the sales of several other Pfizer treatments -including atopic dermatitis treatments tafamidis and abrocitinib, as well as pain medication tanezumab - could surge tremendously. The Bottom Line on Pfizer StockPfizer stock is trading at reasonable levels, as its forward price-earnings ratio is below 13. That's in-line with the valuations of other mega pharma operators like Merck (NYSE:MRK) and GlaxoSmithKline (NYSE:GSK).Pfizer also has a long history of being shareholder-friendly. The dividend yield of PFE stock is 3.4% and the company continues to buyback large amounts of Pfizer stock. PFE bought back $12.2 billion of PFE stock last year.However, there probably will not be any near-term catalysts for PFE stock. The political pressure will remain an overhang on Pfizer stock, especially as we get closer to the presidential election. Meanwhile, it will take some time for the company's pipeline to boost its revenue and profits. As a result, investors shouldn't rush to buy Pfizer stock.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dividend Stocks That Could Double Over the Next Five Years * 6 S&P 500 Stocks Ready to Break Out * 5 Mining ETFs to Dig Into Compare Brokers The post Pfizer Stock Has Positive and Negative Catalysts Going Into Results appeared first on InvestorPlace.

  • Merck and Viola Davis to Debut A Touch of Sugar During Tribeca Film Festival®
    PR Newswire19 hours ago

    Merck and Viola Davis to Debut A Touch of Sugar During Tribeca Film Festival®

    KENILWORTH, N.J., April 25, 2019 /PRNewswire/ -- Merck (MRK), known as MSD outside the United States and Canada, announced today that its documentary film, A Touch of Sugar, will debut during the Tribeca Film Festival on Thursday, April 25 as a part of the company's program, America's Diabetes Challenge: Get to Your Goals. Narrated by award-winning actress and documentary spokesperson Viola Davis, the film dives into the type 2 diabetes healthcare epidemic that affects people in every community across the country, including Davis's own family.

  • Merck (MRK) Gains As Market Dips: What You Should Know
    Zacksyesterday

    Merck (MRK) Gains As Market Dips: What You Should Know

    Merck (MRK) closed at $74.73 in the latest trading session, marking a +0.17% move from the prior day.

  • Why Investors Should Buy the Dip in MRK Stock
    InvestorPlaceyesterday

    Why Investors Should Buy the Dip in MRK Stock

    The collapse of healthcare stocks, especially drug companies, may have finally abated. Merck (NYSE:MRK) has fallen 12% from its April 3 high. But the MRK freefall seems to have finally leveled off.Source: Shutterstock The instinctive reaction would be to buy the dip. Merck's five-year gain is now half that of the average S&P 500 stock, but it's still up 24% in the last year. And what initially sent MRK stock down was fear of politicians, not changes at the business.But Merck stock is still not cheap. Its trailing P/E ratio is 32, and the dividend of 55 cents per share still yields just 2.65% -- lower than many other dividend stocks. That dividend was just hiked in December, and thus isn't due to rise again for 8 more months.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Red-Hot E-Commerce Stocks to Consider Merck is due to report first-quarter earnings on April 30, with $1.05 per share expected on revenue of $10.36 billion. That's a big jump from last year's earnings pace, albeit on less revenue. But if MRK stock keeps growing like this, it would justify both a big dividend hike and an increase in its stock buyback, now at $10 billion on a market cap of $192 billion. The Keytruda MiracleThere are also reasons to find the earnings momentum sustainable.Keytruda, a cancer drug best known for having kept former President Jimmy Carter alive a few years ago, continues to score big with regulators. It's now a first-line drug against advanced kidney cancer, in conjunction with Inlyta from Pfizer (NYSE:PFE).Keytruda is one of three so-called PD-1 inhibitors on the market, alongside Opdivo from Bristol-Myers Squibb (NYSE:BMY) and Libtayo from Regeneron (NASDAQ:REGN). These are monoclonal antibodies that keep cells from attacking one another. Turning off this chemical "off switch" boosts the immune system response to cancer cells. While Opdivo is heavily advertised, it is Keytruda that has been scoring the bigger wins in late-stage studies. The most recent one is Keynote-426, which gave 861 patients two years of the drug, which can cost over $100,000 per year. Keytruda was worth over $7 billion to Merck last year. The Price BacklashIt's Keytruda's price, which doesn't apply in countries that bargain directly for drugs, that caused the healthcare sector's fall from grace this month.That pushback takes many forms, from cost-effectiveness studies to state and national legislation. But the industry's lobbyists still stand strong in Republican Washington.This includes Merck CEO Ken Frazier, who recently agreed to stay on past his normal retirement age for a $20.9 million pay package.Frazier is charged with defending the industry against attacks on its profits and diversifying the company's $42 billion in sales beyond Keytruda, which represents 17% of Merck's total revenue.Merck recently won approval for Mavenclad, a potential blockbuster drug for multiple sclerosis, and it made 60 acquisitions during 2018. These include expansion in animal pharmaceuticals and immunotherapy. Its current late-stage drug pipeline has been valued at $13 billion. The Bottom LineMerck is due to bounce back at least 10%, as the recent downdraft in health care stocks fades from memory, just as the December fall of tech stocks faded.Of 18 analysts now following the stock, 13 now have it on their buy lists and confidence is up over three months ago. * 10 Stocks to Sell Before They Give Back 2019 Gains A beat on the quarterly earnings estimate should be the catalyst to take Merck to new highs, and its pipeline should keep it profitable no matter what Congress decides to do. This is a dip both speculators and investors will enjoy buying.Dana Blankenhorn http://www.danablankenhorn.com is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family https://www.amazon.com/Reluctant-Detective-Finds-Her-Family-ebook/dp/B07FSRDR4Y/, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Oversold Stocks to Run From * 7 Red-Hot E-Commerce Stocks to Consider * 4 Stocks Surging on Earnings Surprises Compare Brokers The post Why Investors Should Buy the Dip in MRK Stock appeared first on InvestorPlace.

  • AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect
    MarketWatch2 days ago

    AbbVie and Bristol-Myers Squibb will report first-quarter earnings on Thursday. Here’s what to expect

    Here’s what investors should look for on Thursday as these two pharmaceutical giants report first-quarter earnings.

  • What to Expect from Merck’s Q1 Revenues and Earnings
    Market Realist2 days ago

    What to Expect from Merck’s Q1 Revenues and Earnings

    What to Expect from Merck’s Q1 2019 Results(Continued from Prior Part)Financial performance in the first quarter Wall Street analysts have forecasted Merck’s (MRK) revenues to be $10.48 billion, $10.92 billion, $11.34 billion, and $11.62 billion,

  • What Are Analysts Recommending for Merck?
    Market Realist2 days ago

    What Are Analysts Recommending for Merck?

    What to Expect from Merck’s Q1 2019 ResultsStock price movements On April 22, Merck (MRK) issued a press release announcing FDA approval for the combination of Keytruda with Pfizer’s (PFE) Inlyta in the first-line advanced RCC (renal cell

  • Kidney-Cancer Market: Good for Patients, Hard for Investors
    Motley Fool2 days ago

    Kidney-Cancer Market: Good for Patients, Hard for Investors

    Drugmakers battle for patients.

  • Why Is Bristol-Myers Near 52-Week Lows?
    InvestorPlace3 days ago

    Why Is Bristol-Myers Near 52-Week Lows?

    Two things are hurting the near-term prospects of Bristol-Myers (NYSE:BMY). First, drug plan companies like UnitedHealth Group (NYSE:UNH) issued a quarterly revenue warning, scaring investors from the drug sector. Second, Bristol-Myers is about to acquire Celgene (NASDAQ:CELG). And as the firm doing the acquiring, markets typically get cautious on short-term risks related to the acquisition.Source: A 4 via Flickr Are these two headwinds enough of a reason to justify BMY stock trading this low? Drug Prices Under PressureWashington is still looking for deterrents to a drug company's ability to raise prices. Any politically driven rules that limit a company's effectiveness to adjust prices will hurt not just Bristol-Myers but most companies in the pharmaceutical space. Companies often need to make adjustments to increase profits. It may then use those profits to pay for research and development, make acquisitions or return profits to shareholders. If this cycle is disrupted, investors will be less inclined to invest in the sector.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAt 15 times earnings, BMY stock is relatively inexpensive compared to its peers. Merck & Co. (NYSE:MRK) fell by around 11% but its shares still trade at 31 times. Pfizer Inc. (NYSE:PFE), which is widely held by investors, trades at 23 times. Markets discounted Bristol-Myers stock because the firm's inability to adjust prices higher will limit the options it has to help pay down the Celgene acquisition. Quarterly Earnings Ahead for BMY StockBMY will report its quarterly results for the quarter ended March 2019 on April 25. First-quarter 2019 earnings are expected to come in at $1.09, up from 94 cents last year. According to Tipranks, analysts are still bullish on BMY stock and have an average price target that is around 33% higher than its $45.52 recent closing price. * 10 High-Yielding Dividend Stocks That Won't Wilt In the upcoming quarter, the firm may shed some light on the progress of Opdivo. Currently, Opdivo has indications for nine different tumors. Management forecasts growth opportunities for Opdivo in the U.S. and outside the U.S., due to its treatment option for two of the tumors. Specifically, the treatment is for adjuvant melanoma and first-line renal cell. BMY launched these indications early last year. Opdivo plus Yervoy will play an important role in first-line renal, so investors should expect a good opportunity for the drug.Regarding Opdivo for cancer treatment, the prospects are more challenging. The company is facing a decline in eligible patients, dropping to the 35%-40% range. Fortunately, Bristol-Myers has a 30% market share. Merits of Celgene Deal for Bristol-Myers ExplainedAt face value, the Celgene buyout will come at a hefty price of $74 billion. Fundamentally though, the two firms coming together will benefit shareholders as a stronger firm. The timing for the deal is good because BMY is strong right now. The strong cash flow will facilitate the management of the debt level. In the long-term, it gets a complementary product line that strengthens its prospects.Revlimid's IP, in particular, has strong prospects ahead. Fortunately, Bristol-Myers forecast a downside and minimal outlook for Revlimid during the negotiation phase. And by preparing for weaker cash flow from it, management may plan out what it needs to do to make the most from the product.Fedratinib, luspatercept and ozanimod have strong commercial viability whose product launch will lead to strong cash flow growth from Celgene. In short, Celgene's specializing in making drugs to treat myeloma will complement BMY's drugs that treat inflammatory diseases. Further, cell therapies will advance BMY in ways that are not possible without the acquisition. ValuationAnalysts are optimistic that BMY stock will increase by over 30% in the next year. When the stock's P/E is below that of its peers, negative emotions are likely to blame for the stock's underperformance. In the near-term, the stock may head even lower as selling pressure accelerates. Still, value investing is all about patience, so starting a position at these levels may pay off over time. Investors who find the stock appealing at these levels will need to hold the stock for at least 2-3 years. By then, Celgene's new product launches will be accretive to Bristol-Myers' results.As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post Why Is Bristol-Myers Near 52-Week Lows? appeared first on InvestorPlace.

  • What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?
    Zacks3 days ago

    What's in the Cards for AstraZeneca (AZN) in Q1 Earnings?

    AstraZeneca (AZN) will report first-quarter results on Apr 26. New drugs likely to drive sales.

  • The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon

    The Zacks Analyst Blog Highlights: Wells Fargo, UnitedHealth, Merck, Schwab and Raytheon

  • Earnings Preview: Merck (MRK) Q1 Earnings Expected to Decline
    Zacks3 days ago

    Earnings Preview: Merck (MRK) Q1 Earnings Expected to Decline

    Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 days ago

    BriaCell Announces Publication at American Society of Clinical Oncology (ASCO) Meeting and Presentation at Precision Breast Cancer Summit in Boston

    BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (BCT.V) (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that BriaCell’s clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings, a supplement to the Journal of Clinical Oncology. ASCO’s Annual Meeting, taking place May 31-June 4, 2019 at the McCormick Place Convention Center in Chicago, IL, represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

  • Reuters4 days ago

    Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

    The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday. The drug was approved in combination with Pfizer Inc's Inlyta to treat advanced renal cell carcinoma. The approval, which comes two months ahead of expectations, allows this combination therapy to get an early launch ahead of other rival products, Cowen analyst Yaron Werber said, after the company received FDA approval on Friday.

  • Business Wire4 days ago

    FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)

    Approval Based on Results of KEYNOTE-426, Where KEYTRUDA in Combination With Axitinib Reduced the Risk of Death by Nearly Half Compared to Sunitinib

  • ETF Trends7 days ago

    Pharmaceutical ETFs Catch Healthcare Contagion

    The retreat in healthcare stocks is bleeding over, with areas like pharmaceutical sector exchange traded funds being dragged down by association. The iShares U.S. Pharmaceuticals ETF (IHE) continued its downward spiral Thursday, falling 0.4%. “Clearly, huge stock impacts to HCA and managed care can’t be ignored and ‘collateral damage’ to sub-sectors like biopharma in the following days are reflective of a view that mutual funds are drawing down and souring” on health care, Jefferies analyst Michael Yee wrote in a note, according to Bloomberg.

  • GuruFocus.com7 days ago

    Keeley Funds Comments on Versum Materials

    Guru stock highlight

  • Clovis Focuses on Rubraca Label Expansion, Competition Stiff
    Zacks8 days ago

    Clovis Focuses on Rubraca Label Expansion, Competition Stiff

    Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.

  • Can Q1 Earnings Lift Healthcare ETFs Higher?
    Zacks8 days ago

    Can Q1 Earnings Lift Healthcare ETFs Higher?

    With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

  • Here Are the Key Takeaways From J&J's Q1 Earnings Report
    Zacks8 days ago

    Here Are the Key Takeaways From J&J's Q1 Earnings Report

    Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

  • Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline
    Zacks8 days ago

    Novo Nordisk's (NVO) Share Price Rises YTD on Strong Pipeline

    Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.